Clinical Trials
- Sarcoma Cancers, Cancer
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
- Ages18 years and older
- GenderBoth
- Sarcoma Cancers, Brain and Other Nervous System Cancers, Other Cancers, Lymphoma, Kidney Cancer, Leukemia, Liver Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Gynecological Cancers, Lung Cancer, Bladder Cancer, Colorectal Cancer, Pediatric Cancers
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Gynecological Cancers
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
- GenderFemale only
- Phase 1 Cancers
Study of ARTS-021 in Patients With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants With Select Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- Gynecological Cancers
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome
- Phase 1 Cancers
PRIMROSE: A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours That Are MTAP Deficient
- Leukemia, Pediatric Cancers
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
- Phase 1 Cancers
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants With Advanced Solid Tumors
A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients With Advanced Solid Tumors Harboring Mutations in the KRAS MAPK Pathway